Safety and Efficacy of Maximally Tolerated RAS Therapy Alone or in Combination With Spironolactone in Diabetic Kidney Disease: Effect on Proteinuria and eGFR in the MRA-ACE Trial

Authors

Nelson Kopyt DO, FASN, FACP, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

11-2022

Volume

33

Issue

11

First Page

677

Last Page

677

Published In/Presented At

Tumlin, James A.1,2; Kopyt, Nelson P.1; Wilson, Daniel J.1; NephroNet Clinical Trials Consortium. Safety and Efficacy of Maximally Tolerated RAS Therapy Alone or in Combination With Spironolactone in Diabetic Kidney Disease: Effect on Proteinuria and eGFR in the MRA-ACE Trial: SA-PO271. Journal of the American Society of Nephrology 33(11S):p 677, November 2022. | DOI: 10.1681/ASN.20223311S1677c

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine

Document Type

Article